ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
1W: -2.4%
1M: -11.1%
3M: -21.1%
YTD: -43.1%
1Y: -50.9%
3Y: +41.8%
5Y: +11.7%
$226.79
-0.87 (-0.38%)
After Hours: $226.09 (-0.70, -0.31%)
Weekly Expected Move ±5.6%
$199
$211
$224
$237
$249
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Balance Sheet Trends
Total Assets
$5.0B
+17.1% ▲
5Y CAGR: +7.8%
Total Liabilities
$4.2B
+0.1% ▲
5Y CAGR: +11.8%
Shareholders Equity
$789M
+1076.3% ▲
5Y CAGR: -4.9%
Cash & Investments
$2.9B
+7.9% ▲
5Y CAGR: +9.2%
Total Debt
$1.3B
-53.4% ▼
5Y CAGR: +19.7%
Net Debt
-$379M
-121.3% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $820M | $866M | $813M | $966M | $1.7B |
| Short-Term Investments | $1.6B | $1.3B | $1.6B | $1.7B | $1.3B |
| Cash & ST Investments | $2.4B | $2.2B | $2.4B | $2.7B | $2.9B |
| Net Receivables | $199M | $238M | $328M | $405M | $778M |
| Inventory | $86M | $129M | $89M | $79M | $83M |
| Other Current Assets | $0 | $133M | $126M | $117M | $282M |
| Total Current Assets | $2.8B | $2.7B | $3.0B | $3.3B | $4.1B |
| Property, Plant & Equip. | $734M | $739M | $726M | $694M | $708M |
| Goodwill & Intangibles | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $101M | $115M | $111M | $134M | $82M |
| Total Non-Current Assets | $835M | $854M | $847M | $945M | $916M |
| Total Assets | $3.6B | $3.5B | $3.8B | $4.2B | $5.0B |
| — Liabilities — | |||||
| Accounts Payable | $73M | $98M | $56M | $88M | $116M |
| Short-Term Debt | $0 | $0 | $0 | $113M | $0 |
| Deferred Revenue | $149M | $42M | $103M | $55M | $5M |
| Other Current Liabilities | $131M | $171M | $177M | $214M | $477M |
| Total Current Liabilities | $696M | $768M | $968M | $1.2B | $1.5B |
| Long-Term Debt | $676M | $1.0B | $1.0B | $2.4B | $1.0B |
| Other Non-Current Liab. | $1.2B | $1.5B | $1.6B | $398M | $1.5B |
| Total Non-Current Liabilities | $2.4B | $2.9B | $3.1B | $3.0B | $2.7B |
| Total Liabilities | $3.1B | $3.7B | $4.1B | $4.2B | $4.2B |
| — Equity — | |||||
| Common Stock | $1M | $1M | $1M | $1M | $1M |
| Retained Earnings | -$5.4B | -$6.6B | -$7.0B | -$7.3B | -$6.7B |
| Accumulated OCI | -$33M | -$45M | -$23M | -$35M | -$20M |
| Total Stockholders Equity | $588M | -$158M | -$221M | $67M | $789M |
| Total Liabilities & Equity | $3.6B | $3.5B | $3.8B | $4.2B | $5.0B |
| — Key Metrics — | |||||
| Total Debt | $998M | $1.3B | $1.3B | $2.7B | $1.3B |
| Net Debt | $178M | $454M | $493M | $1.8B | -$379M |
| Total Investments | $1.6B | $1.3B | $1.6B | $1.7B | $1.3B |